Evaluation of Ocular Surface Changes and Tear Film Parameters in Patients Receiving Long-Term Topical Antiglaucoma Medications
Keywords:
Antiglaucoma medications, Ocular surface disease, Dry eye disease, Tear breakup time, Schirmer's test, OSDI, Benzalkonium chlorideAbstract
Background: Long-term use of topical antiglaucoma medications is associated with ocular surface alterations, tear film instability, and dry eye symptoms, which may adversely affect patient comfort, treatment adherence, and quality of life. Prolonged exposure to multiple medications and ophthalmic preservatives may further contribute to ocular surface dysfunction.
Aim: To evaluate ocular surface changes and tear film parameters in patients receiving long-term topical antiglaucoma medications.
Materials and Methods: A hospital-based observational cross-sectional study was designed to include 110 patients receiving topical antiglaucoma medications for at least six months at a tertiary care hospital. Demographic characteristics, duration of treatment, number of medications, and preservative exposure were assessed. Ocular surface evaluation included the Ocular Surface Disease Index (OSDI), tear breakup time (TBUT), Schirmer's test I, corneal fluorescein staining, and meibomian gland assessment.
Results: In the observed dataset, 77.3% of patients had abnormal OSDI scores, with moderate and severe symptoms observed in 30.9% and 22.7%, respectively. Reduced TBUT was recorded in 74.5%, decreased Schirmer's test values in 59.1%, and corneal fluorescein staining in 54.5%. Mean OSDI scores increased from 18.4 ± 8.6 among patients receiving monotherapy to 36.5 ± 11.8 among those receiving three or more medications. Patients receiving preservative-containing formulations had higher mean OSDI scores (29.8 ± 11.6) than those receiving preservative-free formulations (17.5 ± 8.4).
Conclusion: The observed findings suggest that greater medication burden, prolonged treatment duration, and preservative exposure may be associated with increased ocular surface dysfunction. Routine assessment of tear film parameters and individualized glaucoma therapy may help improve ocular comfort and treatment adherence.
References
Srivastava K, Bhatnagar KR, Shakrawal J, Tandon M, Jaisingh K, Pandey L, et al. Ocular surface changes in primary open-angle glaucoma on anti-glaucoma medications versus treatment-naïve patients. Indian J Ophthalmol. 2024;72(3):374-80.
Kemer ÖE, Mekala P, Dave B, Kooner KS. Managing ocular surface disease in glaucoma treatment: a systematic review. Bioengineering (Basel). 2024;11(10):1010.
Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276-83.
Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3):539-74.
Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350-5.
Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618-21.
Wong ABC, Wang MTM, Liu K, Prime ZJ, Danesh-Meyer HV, Craig JP, et al. Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye. Ocul Surf. 2018;16(3):289-93.
Ramli N, Supramaniam G, Samsudin A, Juana A, Zahari M, Choo MM, et al. Ocular surface disease in glaucoma: effect of polypharmacy and preservatives. Optom Vis Sci. 2015;92(9):e222-6.
Baudouin C, Renard JP, Nordmann JP, Denis P, Lachkar Y, Sellem E, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2013;23(1):47-54.
Saini M, Vanathi M, Dada T, Agarwal T, Dhiman R, Khokhar S, et al. Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy. Int J Ophthalmol. 2017;10(6):931-8.
Awe OO, Onakpoya OH, Adeoye AO. Effect of long-term topical antiglaucoma medication use on the ocular surface. Niger Med J. 2020;61(4):184-8.
Cascaldi BG, Cardoso Filho AP, Arruda GV, Rocha EM, Paula JS. Topical anti-glaucoma medications effects on meibomian glands: systematic review and meta-analysis. Ocul Surf. 2024;34:183-93.
Ocular surface parameters in glaucoma patients treated with topical prostaglandin analogs and the importance of switching to preservative-free eye drops: a systematic review. Life (Basel). 2025;15(12):1837.
Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res. 2011;36(5):391-8.
Messmer EM, Baudouin C, Benitez-Del-Castillo JM, Iester M, Anton A, Thygesen J, et al. Expert consensus recommendations for the management of ocular surface inflammation in patients with glaucoma. J Glaucoma. 2024;33(10):715-27.
Garcia-Feijoo J, Sampaolesi JR. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin Ophthalmol. 2012;6:441-6.
Pérez-Bartolomé F, Martínez-de-la-Casa JM, Arriola-Villalobos P, Fernández-Pérez C, Polo V, García-Feijoó J, et al. Ocular surface disease in patients under topical treatment for glaucoma. Eur J Ophthalmol. 2017;27(6):694-704.
Kobia-Acquah E, Gyekye GAP, Antwi-Adjei EK, Koomson NY, Cobbina F, Donkor R, et al. Assessment of ocular surface disease in glaucoma patients in Ghana. J Glaucoma. 2021;30(2):180-6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Dr. Bhadra Priya et al

This work is licensed under a Creative Commons Attribution 4.0 International License.



